Prostate Cancer
23andMe Gains FDA Clearance for Direct-to-Consumer Prostate Cancer Genetic Risk Test
The firm is now authorized to sell a genetic health report on the HOXB13 marker that indicates risk for hereditary prostate cancer, its third DTC cancer risk report with 510(k) clearance.
Rarecells Raises $13M in Series A Round to Develop Liquid Biopsy Early Cancer Detection Tests
The company is planning to develop circulating tumor cell assays for prostate cancer and acute myeloid leukemia and to launch them in the US.
The company is embarking on its own diagnostic plans as it prepares to market its platform for external test development following FDA clearance.
Caris Life Sciences, Essa Pharma Ink Liquid Biopsy Partnership for Prostate Cancer Trial
Essa will use Caris' blood-based sequencing tests to assess the genetic profiles of mCRPC patients enrolled in a Phase I trial of the firm's investigational agent.
Polygenic Risk Scores for Breast, Prostate Cancer Adaptable for Cross-Ancestry Use, Study Shows
The researchers said the approach could be a short-term measure while genetic studies of more diverse ancestral populations are performed.